Ariane Laparra

943 total citations · 1 hit paper
21 papers, 503 citations indexed

About

Ariane Laparra is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Ariane Laparra has authored 21 papers receiving a total of 503 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Immunology. Recurrent topics in Ariane Laparra's work include Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (7 papers) and CAR-T cell therapy research (4 papers). Ariane Laparra is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (7 papers) and CAR-T cell therapy research (4 papers). Ariane Laparra collaborates with scholars based in France, United States and Cyprus. Ariane Laparra's co-authors include Olivier Lambotte, Jean‐Marie Michot, Stéphane Champiat, Aurélien Marabelle, Christophe Massard, Jérôme Le Pavec, Antoine Hollebecque, Aurore Vozy, Michael Collins and Anne Laure Voisin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Antimicrobial Agents and Chemotherapy and Annals of Oncology.

In The Last Decade

Ariane Laparra

16 papers receiving 497 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

2019 272 citations Audrey Simonaggio, Jean‐Marie Michot et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ariane Laparra France	9	365	146	89	71	59	21	503
Gary W. Jean United States	7	239 0.7×	92 0.6×	80 0.9×	78 1.1×	35 0.6×	14	375
Eli P. Darnell United States	6	258 0.7×	167 1.1×	93 1.0×	60 0.8×	34 0.6×	10	406
Ioannis P. Trontzas Greece	11	153 0.4×	88 0.6×	36 0.4×	97 1.4×	25 0.4×	32	338
Charlotte Mussini France	11	488 1.3×	89 0.6×	141 1.6×	84 1.2×	215 3.6×	36	702
Tatsunori Kiriu Japan	13	199 0.5×	186 1.3×	54 0.6×	119 1.7×	17 0.3×	26	460
Rohan Mandaliya United States	10	242 0.7×	65 0.4×	76 0.9×	32 0.5×	86 1.5×	31	421
Daniel Leino United States	7	123 0.3×	53 0.4×	47 0.5×	50 0.7×	20 0.3×	20	290
Jian‐Bao Xin China	13	202 0.6×	323 2.2×	238 2.7×	106 1.5×	56 0.9×	25	626
Dominik A. Barth Austria	15	222 0.6×	120 0.8×	74 0.8×	284 4.0×	38 0.6×	36	600

Countries citing papers authored by Ariane Laparra

Since Specialization

Citations

This map shows the geographic impact of Ariane Laparra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ariane Laparra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ariane Laparra more than expected).

Fields of papers citing papers by Ariane Laparra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ariane Laparra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ariane Laparra. The network helps show where Ariane Laparra may publish in the future.

Co-authorship network of co-authors of Ariane Laparra

This figure shows the co-authorship network connecting the top 25 collaborators of Ariane Laparra. A scholar is included among the top collaborators of Ariane Laparra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ariane Laparra. Ariane Laparra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Champiat, Stéphane, Ariane Laparra, Andreas Charalambous, et al.. (2025). From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug development. ESMO Open. 10(10). 105796–105796.

Laparra, Ariane, Stéphane Champiat, François‐Xavier Danlos, et al.. (2025). Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 13(9). e012756–e012756.

Simon‐Tillaux, Noémie, Stefan Michiels, Lisa Derosa, et al.. (2025). Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non–Small-Cell Lung Cancer. JAMA Network Open. 8(9). e2529225–e2529225. 1 indexed citations

Laparra, Ariane. (2025). Immuno-oncology in the daily practice. Current Opinion in Oncology. 37(2). 136–141. 1 indexed citations

Baldini, Capucine, Ariane Laparra, Olivier Lambotte, et al.. (2024). Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer. SHILAP Revista de lepidopterología. 5. 100061–100061. 4 indexed citations

Franzoi, Maria Alice, Arnaud Pagès, Antonio Di Meglio, et al.. (2024). Evaluating the Implementation of Integrated Proactive Supportive Care Pathways in Oncology: Master Protocol for a Cohort Study. JMIR Research Protocols. 13. e52841–e52841. 2 indexed citations

Laparra, Ariane, Madona Sakkal, François‐Xavier Danlos, et al.. (2024). Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations. Cancer Treatment Reviews. 127. 102751–102751. 36 indexed citations

Laparra, Ariane, et al.. (2023). Principaux troubles hydro-électrolytiques chez le patient de cancérologie. Bulletin du Cancer. 111(7-8). 687–700.

Hardy‐Léger, Isabelle, Mathilde de Menthon, Ariane Laparra, et al.. (2023). Psychiatric Symptoms and Cognitive Disorders in Behçet’s Disease: A Single-Center, Cross-Sectional Study. Journal of Clinical Medicine. 12(9). 3149–3149. 6 indexed citations

10.

Laparra, Ariane, François‐Xavier Danlos, Antoine Hollebecque, et al.. (2023). Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology. European Journal of Cancer. 193. 113313–113313. 11 indexed citations

11.

Baldini, Capucine, Ariane Laparra, Madona Sakkal, et al.. (2023). 263P Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data. Annals of Oncology. 34. S288–S288.

12.

Besse, Benjamin, Ariane Laparra, Nicolas Noël, et al.. (2022). Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors. Respiratory Medicine and Research. 82. 100969–100969. 13 indexed citations

13.

Laparra, Ariane, François‐Xavier Danlos, Stéphane Champiat, et al.. (2021). The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. European Journal of Cancer. 158. 217–224. 58 indexed citations

14.

Éderhy, Stéphane, Stéphane Champiat, Frédéric Troalen, et al.. (2021). Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. European Journal of Cancer. 157. 383–390. 6 indexed citations

15.

Labeyrie, Céline, Andoni Echaniz‐Laguna, Ariane Laparra, et al.. (2021). Neuropathies périphériques associées aux syndromes lymphoprolifératifs : spectre clinique et démarche diagnostique. La Revue de Médecine Interne. 42(12). 844–854.

16.

Laparra, Ariane, Maria Kfoury, Stéphane Champiat, et al.. (2021). Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?. Annals of Oncology. 32(7). 936–937. 5 indexed citations

17.

Laparra, Ariane, Sabine Tricot, Jennifer Gorwood, et al.. (2019). The Frequencies of Immunosuppressive Cells in Adipose Tissue Differ in Human, Non-human Primate, and Mouse Models. Frontiers in Immunology. 10. 117–117. 26 indexed citations

18.

Simonaggio, Audrey, Jean‐Marie Michot, Anne Laure Voisin, et al.. (2019). Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncology. 5(9). 1310–1310. 272 indexed citations breakdown →

19.

Burdet, Charles, Thu Thuy Nguyen, Xavier Duval, et al.. (2019). Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity. Antimicrobial Agents and Chemotherapy. 63(10). 39 indexed citations

20.

Mellon, Guillaume, Bernard Henry, Olivier Aoun, et al.. (2016). Adenovirus related lymphohistiocytic hemophagocytosis: Case report and literature review. Journal of Clinical Virology. 78. 53–56. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact